Pfizer Inc (PFE) Stock Price, Trades & News

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.19
Equity-to-Asset	0.42
Debt-to-Equity	0.74
Debt-to-EBITDA	4.68
Interest Coverage	6.31
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.1	Distress Grey Safe
Beneish M-Score	-2.44	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

3/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-14.7
	3-Year EBITDA Growth Rate	-25.7
	3-Year EPS without NRI Growth Rate	-21.2
	3-Year FCF Growth Rate	-29.5
	3-Year Book Growth Rate	-3.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	-7.66
	Future 3-5Y Total Revenue Growth Rate Estimate	-4.13

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	52.05
	9-Day RSI	60.03
	14-Day RSI	62.51
	3-1 Month Momentum %	-1.09
	6-1 Month Momentum %	-4.55
	12-1 Month Momentum %	3.55

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.27
	Quick Ratio	0.96
	Cash Ratio	0.36
	Days Inventory	232.46
	Days Sales Outstanding	72.53
	Days Payable	104.76

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	6.05
	Dividend Payout Ratio	0.56
	3-Year Dividend Growth Rate	2.4
	Forward Dividend Yield %	6.05
	5-Year Yield-on-Cost %	6.85
	3-Year Average Share Buyback Ratio	-0.4
	Shareholder Yield %	6.17

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	73.18
	Operating Margin %	26.72
	Net Margin %	6.8
	EBITDA Margin %	21.18
	FCF Margin %	17.25
	OCF Margin %	21.04
	ROE %	4.89
	ROA %	2.1
	ROIC %	8.99
	3-Year ROIIC %	-121.21
	ROC (Joel Greenblatt) %	36.2
	ROCE %	4.05
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	6

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	37.43
	Forward PE Ratio	9.83
	PE Ratio without NRI	9.28
	Shiller PE Ratio	10.09
	Price-to-Owner-Earnings	41.29
	PS Ratio	2.55
	PB Ratio	1.9
	Price-to-Free-Cash-Flow	14.82
	Price-to-Operating-Cash-Flow	12.14
	EV-to-EBIT	30.98
	EV-to-Forward-EBIT	11
	EV-to-EBITDA	15.86
	EV-to-Forward-EBITDA	8.93
	EV-to-Revenue	3.36
	EV-to-Forward-Revenue	3.53
	EV-to-FCF	19.48
	Price-to-GF-Value	1.07
	Price-to-Projected-FCF	0.78
	Price-to-Median-PS-Value	0.69
	Earnings Yield (Greenblatt) %	3.23
	FCF Yield %	6.77
	Forward Rate of Return (Yacktman) %	-7.88

GF Value™: $26.48

PFE

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with PFE. Try a 7-Day Free Trial to check it out.

Pfizer Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Pfizer Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Annual report for 2026	2027-02-26	In 172 days
Fourth quarter earnings conference call for 2026	2027-02-03 10:00	In 150 days
Fourth quarter earnings results for 2026	2027-02-03	In 149 days
Third quarter earnings conference call for 2026	2026-11-04 10:00	In 59 days
Third quarter earnings results for 2026	2026-11-04	In 58 days
Second quarter earnings conference call for 2026	2026-08-04 10:00	25.03 (-0.48%)
Second quarter earnings results for 2026	2026-08-04	25.03 (-0.48%)
USD 0.430000 Cash Dividend	2026-07-24	25.01 (+0.48%)
Jefferies Global Healthcare Conference	2026-06-03 14:00	25.55 (-0.20%)
USD 0.430000 Cash Dividend	2026-05-08	26.48 (-0.15%)

Show

Entries

Guru Commentaries on NYSE:PFE

No fund manager commentary yet.

Browse all fund letters →

Press Release

	Subject	Date
	Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine	2026-08-27
	Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency	2026-08-14
	Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance	2026-08-04
	Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo	2026-07-30
	European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union	2026-07-29
	FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer	2026-07-22
	U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility	2026-07-10
	Pfizer Declares Third-Quarter 2026 Dividend	2026-06-24
	FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance	2026-06-24
	Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts	2026-06-23

10/Page

Articles on Pfizer Inc

PFE

Pfizer's Updated COVID Shot Ships Into a Smaller Market

Aug 28, 2026

PFE

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Aug 27, 2026

PFE

PFE Looks 5.7% Overvalued on GF Value™ Amid FDA Approval for Updated COVID-19 Vaccine

Aug 27, 2026

PFE

A Look at Pfizer Inc (PFE) After 3.6% Gain -- GF Value $26.53 vs Price $28.24

Aug 19, 2026

PFE

Pfizer Inc (PFE): A Closer Look Behind a 68 GF Score

Aug 19, 2026

Headlines

Sep 07, 2026

Novartis India inks $132M asset purchase deal with Pfizer for Minipress brands

Seeking Alpha • 1:24am

Sep 04, 2026

RFK Jr. is probing if U.S. troops died of COVID shots: report

Seeking Alpha • 6:36am

Sep 03, 2026

Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate

Seeking Alpha • 9:52am

Aug 28, 2026

Novavax announces regulatory approvals for updated COVID shot

Seeking Alpha • 8:25am

Pfizer-backed Priovant wins FDA approval for lead asset

Seeking Alpha • 5:48am

Aug 27, 2026

Pfizer, BioNTech win approval for updated COVID-19 shot

Seeking Alpha • 4:16pm

HHS advisors to discuss boosting funding for autism care

Seeking Alpha • 10:02am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.